CREB1 and thyroid cancer, nonmedullary, 2: The CREB1 gene exhibited decreased expression in both the malignant sample group (PTC and FTC) (group 2) and the FTC sample group (group 5) compared to the group of normal and benign samples (group 1) through PCR array validated by RT-qPCR analysis, indicating its potential as a molecular diagnostic marker for distinguishing between benign and malignant neoplasms.